Obesity is a complex disease that affects a substantial portion of the world’s population. CB1 receptors are related to every key organ that is related to metabolism, underlying the key effects of blocking these receptors in the clinic without ever crossing the blood brain barrier.
Skye’s CBeyond Trial proof of mechanism trial that compares weight loss in patients treated with nimacimab vs placebo. A second arm in the study compares the effect of nimacimab combined with semaglutide vs semaglutide alone given with placebo.